Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer
February 04, 2015 10:05 ET
|
Qu Biologics;BC Cancer Agency
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...
Qu Biologics Begins Research with McMaster University to Study New Crohn's Disease Research Model
December 03, 2013 10:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to stimulate the...
Qu Biologics Initiates Study of Site Specific Immunomodulators at Geisel School of Medicine at Dartmouth
July 03, 2013 12:00 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 3, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's...
Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn's Disease
June 11, 2013 16:22 ET
|
Qu Biologics
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the...